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Abstract
Gynaecological malignancies are the most common malignancies in women and also an important public health 
issue. In developing countries, there is a paucity of screening facilities and cancer awareness, so patients present  
at an advanced stage of disease, which severely limits the prognosis and clinical outcome. Among the gynaecological 
malignancies, ovarian malignancy has the second highest incidence in women according to the incidences. Ovarian 
malignancy is usually diagnosed at the advanced stages, and to improve the patient’s survival, debulking surgery is 
very important. Advanced-stage disease is treated with either debulking surgery followed by adjuvant chemotherapy 
or initial neoadjuvant chemotherapy followed by debulking surgery. Imaging is very important in patient selection, in 
determining who will benefit from neoadjuvant chemotherapy just before debulking surgery. This article highlights 
the role of computed tomography (CT) in the detection of patterns of spread of ovarian malignancy, important for 
staging and management. 
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Introduction
Ovarian cancer is the fifth most common malignancy 
among women worldwide and the second most common 
gynaecological malignancy [1]. Ovarian malignancy is 
usually diagnosed at advanced stage of the disease with 
five-year survival rate in stage III disease being 37% and 
stage IV disease being 24% [2]. The International Federa-
tion of Gynaecology and Obstetrics (FIGO) ovarian cancer 
staging system was first published in 1973 and was revised 
in 1988 and 2014. Table 1 and Figure 1 summarise the new 
FIGO 2014 staging of ovarian cancer [3,4]. 
The treatment planning of advanced ovarian malig-
nancies includes both primary debulking surgery followed 
by adjuvant chemotherapy, and if non-resectable disease 
is found on preoperative imaging, neoadjuvant chemo-
therapy followed by debulking surgery. Several recent ran-
domised control trials clearly show similar disease-free 
survival rates between stage III or stage IV disease in pa-
tients who initially underwent chemotherapy followed by 
debulking surgery [5]. 
Detection of peritoneal disease on preoperative imag-
ing is very difficult, and interpretation of imaging findings 
requires in-depth knowledge of complex peritoneal anato-
my, peritoneal fluid flow direction, and specific anatomic 
locations where debulking surgery is technically difficult. 
The presence of disease at these sites is very helpful for 
surgeons for planning of surgery. 
This article describes the role of radiologists in plan-
ning the management of advanced ovarian malignancies. 
Radiologists provide essential information about routes of 
disease dissemination and common sites for intra- and ex-
traperitoneal disease. Preoperative imaging is very helpful 
in detection of sites of potentially non-resectable disease 
or resectable disease, which is very helpful in the planning 
of debulking surgery. Early signs of peritoneal spread of 
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Table 1. FIGO staging of ovarian cancer 2014 [3,4]
Stage I
Tumour confined to ovaries
IA:  Tumour limited to one ovary or fallopian tube, capsule intact, no tumour on surface, no tumour 
cells in ascites or washings
IB: Tumour involves both ovaries or fallopian tubes, otherwise like stage IA
IC:  Tumour involves one or both ovaries with any of the following: capsule rupture, tumour on surface 
of the ovary, positive peritoneal washings or ascites
      IC1: Intraoperative spill
      IC2: Capsule rupture before surgery or tumour on ovarian or fallopian tube surface
      IC3: Malignant cells in the ascites or peritoneal washings
Stage II
Tumour involves one or both ovaries with 
pelvic extension (below the pelvic brim)  
or primary peritoneal cancer
IIA: Extension and/or implant on uterus and/or fallopian tubes
IIB: Extension to other pelvic intraperitoneal tissues
Stage III
Tumour involves one or both ovaries with 
cytological or histologically confirmed spread 
to the peritoneum outside the pelvis and/or 
metastasis to the retroperitoneal lymph nodes
IIIA: Positive retroperitoneal lymph nodes and /or microscopic metastasis beyond the pelvis
      IIIA1: Positive retroperitoneal lymph nodes only
            IIIA1(i) Metastasis ≤ 10 mm
            IIIA1(ii) Metastasis > 10 mm
      IIIA2:  Microscopic, extrapelvic (above the brim) peritoneal involvement ± positive retroperitoneal 
lymph nodes
IIIB: Macroscopic, extrapelvic, peritoneal metastasis ≤ 2 cm ± positive retroperitoneal lymph nodes. 
Includes extension to capsule of liver/spleen
IIIC: Macroscopic, extrapelvic, peritoneal metastasis > 2 cm ± positive retroperitoneal lymph nodes. 
Includes extension to capsule of liver/spleen
Stage IV:
Distant metastasis excluding peritoneal 
metastasis
IVA: Pleural effusion with positive cytology
IVB:  Hepatic and/or splenic parenchymal metastasis, metastasis to extra-abdominal organs 
(including inguinal lymph nodes and lymph nodes outside of the abdominal cavity)
Figure 1. Drawing showing FIGO staging of ovarian cancer
ovarian malignancy may be missed if subtle deposits are 
not detected. Precise interpretation of ovarian malignancy 
spread on computed tomography is necessary for good 
quality reporting of ovarian malignancies for optimal 
management of disease.
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Clinical and laboratory findings in ovarian cancer
Early stage ovarian cancers are usually asymptomatic. 
Late-stage ovarian cancers, which account for approxi-
mately 60% of cases, often have nonspecific symptoms, not 
recognised as symptoms of cancer [6]. Nonspecific symp-
toms of ovarian cancer are back pain, fatigue, abdominal 
pain/bloating, constipation, or urinary symptoms.
In addition to these nonspecific symptoms, ovarian 
cancer may present with paraneoplastic syndromes such 
as subacute cerebellar degeneration; sudden onset of 
seborrheic keratoses (Leser-Trélat sign); or unexplained 
spontaneous, recurrent, or migratory venous thrombot-
ic events (Trousseau syndrome). Advanced disease may 
present with symptoms of regional spread or metastasis, 
such as bowel or ureteral obstruction, or shortness of 
breath [7,8]. Sex cord-stromal tumours can present ear-
ly at stage I because of hormonal manifestations such as 
precocious puberty, abnormal uterine bleeding, and viri-
lisation [9].
Cancer antigen (CA) 125 is the biomarker common-
ly tested for ovarian cancer. CA125 is elevated in about 
80% of epithelial ovarian cancers overall, but in only 50% 
of early-stage epithelial ovarian cancers [8]. Biomarkers 
for nonepithelial ovarian cancers include inhibin A/B for 
sex cord–stromal tumours, and serum α-fetoprotein and 
quantitative beta human chorionic gonadotropin for germ 
cell tumours [10]. Human epididymal protein 4 (HE4) is 
a relatively new tumour marker. Elevated serum HE4 lev-
els have been shown to have higher sensitivity (89%) and 
specificity (92%) than CA125 for distinguishing ovarian 
cancer from benign ovarian disease in premenopausal 
women, particularly in early-stage disease. As well as 
these biomarkers, complete blood count, blood chemis-
try including liver function tests and calcium (to assess for 
paraneoplastic syndromes), and serum biomarkers should 
be obtained if ovarian cancer is suspected.
Computed tomography technique
The optimal abdominal and pelvic computed tomogra-
phy (CT) technique for staging ovarian cancer includes 
water as an oral contrast media, and in the absence of 
contraindications to intravenous contrast media, the use 
of intravenous contrast media is mandatory. Opacifica-
tion of the gastrointestinal tract with oral contrast media 
helps to distinguish between luminal lesions and serous 
or mesenteric deposits; however, small, calcified deposits 
may be masked by oral contrast [11]. At our institution, 
image acquisition is done at 70 seconds after injection of 
contrast media. Acquisition for an abdominal and pelvic 
CT extends from the lower thorax to the inguinal regions 
with reconstruction of images with an axial slice thickness 
of 1-2 mm [10]. To include chest or not is an institutional 
policy. At our institute, we routinely scan the whole chest 
to look for lung metastases.
Routes of dissemination
Ovarian cancer usually spreads by direct infiltration into 
surrounding pelvic organs. Ovarian malignancies most 
commonly involve the adjacent adnexal structures like the 
uterus, fallopian tube, and contralateral ovary. Pelvic organs 
like the rectum, sigmoid colon, urinary bladder, and pelvic 
side wall may also be invaded. Spread of ovarian malignan-
cy outside the pelvis occurs by intraperitoneal seeding, lym-
phatic transmission, or haematogenous spread.
Intraperitoneal seeding
Intraperitoneal seeding is most common mode of spread of 
ovarian malignancy, and during laparotomy 70% patients 
have peritoneal metastasis. The ovary is covered by single 
layer of epithelium and in epithelial ovarian malignancy, 
tumour cells are detached from the epithelium and spread 
in peritoneal fluid. Tumour cells initially shed into the de-
pendent aspect of the rectouterine pouch and then move 
into lateral paravesical region because of gravity, and then 
move in a cranial direction with circulating peritoneal fluid 
through the right paracolic gutter to the hepatorenal pouch, 
right subphrenic space and then inferiorly into the inframe-
socolic compartment (Figure 2). The rectouterine pouch, 
right lower quadrant, sigmoid colon, and right paracolic 
gutter are the most common sites for peritoneal deposits 
due to gravity-dependent areas in the peritoneal cavity [12]. 
Peritoneal deposits are most commonly seen in the right 
paracolic gutter rather than the left due to the presence of 
the phrenicocolic ligament on the left side.
Lymphatic dissemination
Ovaries have three main drainage pathways – paraaortic 
and paracaval nodes are most common sites of lymph node 
metastasis, and they are drained by lymphatic vessels that 
follow the ovarian veins. The second most common site of 
lymph node metastasis is along the external iliac and ob-
turator lymph nodes along the broad ligament (Figure 3) 
and inguinal lymph nodes along the round ligament [13].
Haematogeneous spread
Haematogeneous spread is the least common mode of 
spread of ovarian malignancy. It often involves colon, liv-
er, small intestine, and lung in decreasing order. Ovari-
an malignancy can rarely involve the spleen, kidney, and 
brain (Figure 4) [14].
Sites of tumour dissemination
Peritoneal involvement
Visible metastatic implants outside the pelvis and retrop-
eritoneal lymphadenopathy are seen in 60% of epithelial 
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ovarian malignancy [15]. Subtle thickening, nodularity, 
soft tissue in omental fat, peritoneal enhancement, and 
loculated ascites are subtle signs of peritoneal spread 
(Figure 5). Negative oral contrast is recommended for the 
detection of subtle serous deposits on the bowel surface.
Morphologically, there are three types of implants: sol-
id, cystic, and mixed. In all three categories, calcifications 
may or may not be present. Different patterns of implants 
have been described:
• micronodular pattern – characterised by the presence 
of tiny 1-5-mm nodules involving the serosa and sub-
serosal fat;
• nodular pattern – more than 5-mm-sized nodules, which 
are oval or round in shape with spiculated margins;
Figure 2. A) Drawing showing the peritoneal space anatomy and pathways 
of spread of tumour cells into the peritoneal cavity. B) Coronal contrast-en-
hanced CT showing tumoural deposits into the peritoneal cavity along the 
serous surface, perihepatic space, paracolic spaces, ligaments, lymph nodes, 
and pelvis
Figure 3. Lymphatic dissemination in a case of ovarian cancer: A) Contrast-enhanced CT images showing enlarged lymph node (white arrow) in right 
common iliac region with calcific foci; B) bilateral internal iliac (black arrow) and left external iliac group (white arrow); C) obturator group (white arrow) 
with a deposit in rectouterine pouch (arrowhead)
Figure 4. Haematogeneous spread from ovarian cancer: A) Contrast-enhanced CT images showing large metastatic deposit in liver (black arrow) and spleen 
(white arrow); B) and multiple metastatic nodules in bilateral lungs
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• plaque-like pattern – confluence of nodular implants 
giving a sheet-like pattern typically found in subdia-
phragmatic spaces;
• mass-like pattern – similar to plaque-like pattern, 
commonly found in the pelvis;
• omental cake – diffuse involvement of greater omen-
tum with fibrotic reaction leading to consolidation of 
omental fat;
• teca aspect or ileal freezing – sleeve-like covering of 
small bowel loops by thickened a layer of visceral peri-
toneum with or without bowel obstruction;
• calcified implants – nodular calcific deposits in peri-
toneum along with calcified lymph nodes, especially 
seen in serous ovarian adenocarcinoma;
• neoplastic ascites – free fluid in the peritoneal cavity 
may be due to increased capillary permeability and 
fluid production or blockage of lymphatics leading to 
decreased absorption.
Mesentery
Implantation of tumour cells in small bowel mesentery is 
seen usually surrounding the terminal ileum. Morpho-
logical appearances of mesenteric involvement can be in 
the form of plaque-like thickening, reticulonodular le-
sions, subtle soft tissue haziness, or a mass-like deposit 
(Figure 6).
Lymph nodes
The presence of enlarged suprarenal lymph nodes at the 
level of the celiac axis, porta hepatis, and cardiophrenic 
lymph nodes makes the disease prone to suboptimal re-
section, and patients should go for neoadjuvant chemo-
therapy before surgery [16].
Pelvis
Pelvic side wall invasion should be suspected when the 
mass lesion is within 3 mm of the pelvic side wall, or sur-
rounds or distorts more than 90% of the circumference of 
iliac vessels (Figure 7) [17].
Figure 5. Contrast-enhanced computed tomography showing various types of peritoneal involvement in peritoneal carcinomatosis: A) subtle thickening 
and fat stranding; B) nodular pattern C); mass-like pattern with neoplastic ascites
Figure 6. Contrast-enhanced computed tomography image showing nod-
ular deposits (arrowheads) in mesentery
Figure 7. Pelvic involvement in ovarian cancer – contrast-enhanced com-
puted tomography image showing tense ascites with plaque-like thickening 
of the peritoneum encasing the bilateral iliac vessels (arrows)
A B C
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Visceral surfaces
Liver
The location, site, and size of liver implants should be 
documented in the report. Deposits in the region of Mor-
rison’s pouch, inferior vena cava, and around the right 
hepatic vein must be documented, because deposits in 
this region can cause excessive haemorrhage at the time 
of surgery. Secondary invasion of surface or subserosal 
implant (Figure 8) into the liver parenchyma should be 
well documented in the report [16].
Spleen
Subcapsular splenic deposits and parenchymal metastases 
have to be differentiated because this allows the surgeon 
to decide between splenectomy and spleen-sparing sur-
gery (Figure 9) [17].
Subphrenic space
Right subphrenic involvement is very common because of 
preferential flow of peritoneal fluid from the right para-
colic gutter. Involvement of the subphrenic region is best 
visualised in coronal and sagittal sections of post-contrast 
CT images. Imaging features of sub phrenic involvement 
include the presence of nodules, masses, thickening, and 
enhancement of the hemi diaphragm. Finding of sub-
phrenic involvement must be written in radiologists’ re-
ports because sub phrenic involvements usually require 
upper-quadrant peritonectomy (Figure 10) [18,19].
Bowel
Magnetic resonance imaging (MRI) is superior to CT for 
assessment of bowel involvement in ovarian malignancies. 
Imaging findings of bowel involvement in ovarian malig-
nancy include segmental or focal bowel wall thickening, 
focal nodules, serous infiltrations, or any definitive mass. 
Extensive bowel resections are not recommended due to 
functional complications (Figure 11) [20-22].
Pleural cavity
The presence of pleural effusion must be documented, al-
though this finding is not specific unless tumour cells are 
detected in the fluid cytology.
Figure 9. Subcapsular splenic deposit. Contrast-enhanced computed to-
mography image showing subcapsular splenic deposit (black arrow) and 
another nodular deposit in the gastrosplenic ligament (white arrow)
Figure 10. Subphrenic deposit in ovarian cancer. Coronal contrast-enhanced 
computed tomography image showing nodular thickening in right sub-
phrenic region (arrowheads) indenting the liver surface
Figure 8. Subserosal deposits in ovarian cancer. Contrast-enhanced computed tomography images in two different patients showing subserosal implants 
in liver surface (arrow)
A B
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Ligaments
Greater omentum
Imaging features of involvement of greater omentum 
range from infiltrative fat stranding to discrete and conflu-
ent masses forming omental cake. Involvement of trans-
verse mesocolon also has to be commented upon because 
a modified surgical approach is required for the same.
Lesser omentum
The lesser omentum is a part of the peritoneum, which 
suspends the lesser curvature of the stomach, and it is 
composed of gastro-hepatic ligament and hepatoduodenal 
ligament. The left gastric artery, vein, and gastro-hepatic 
lymph nodes are contents of the gastro hepatic ligament, 
and it is recognised by identification of the left gastric ar-
tery on post-contrast CT images. The portal vein, com-
mon bile duct, hepatic artery, and portocaval lymph nodes 
are content of the hepatoduodenal ligament. Subtle soft 
tissues in the lesser omentum, and nodules and lymphad-
enopathy in the gastro hepatic and hepatoduodenal liga-
ments must be written in radiology reports. Involvement 
of the lesser omentum precludes surgery because of the 
Figure 12. Lesser omentum involvement in ovarian cancer. Axial and coronal CT images showing soft tissue deposits in gastrohepatic ligament (white 
arrow) and in hepatoduodenal ligament (black arrow) of lesser omentum region. Perisplenic and perihepatic enhancing deposits (dashed arrows) with 
neoplastic ascites also evident
complicated anatomy of the lesser omentum, which poses 
significant surgical challenges (Figure 12) [18,19].
Lesser sac
The lesser sac is a potential space between the stomach and 
pancreas. The lesser sac on the left side is outlined by the 
splenorenal ligament, gastrosplenic ligament, and spleno-
pancreatic ligament. The lesser sac, on the right side, con-
nects with the greater sac through the foramen of Winslow. 
Involvement of the lesser sac must be included in the ra-
diological report because its involvement makes ovarian 
malignancy unresectable. Thickening, nodule, mass, fat 
stranding, and the presence of fluid in the lesser sac are 
considered to be signs of disease involvement (Figure 13).
Perihepatic space
The gallbladder fossa and fissure for the falciform liga-
ment are the main components of the perihepatic space. 
Involvement of the falciform ligament should be looked 
for carefully in multiple planes to differentiate from liver 
parenchymal lesions. The falciform ligament, gallbladder 
fossa and periportal space should be carefully evaluated, 
because deposits more than 2 cm in size are predictors of 
non-optimal debulking (Figure 14) [23].
Differential diagnosis and computed 
tomography mimics of peritoneal carcinomatosis
Various pathologies involving the peritoneum can mimic 
peritoneal carcinomatosis. Table 2 summarises the mimics 
of peritoneal carcinomatosis and their imaging features 
[24-33].
Comparison between computed tomography 
and magnetic resonance imaging  
in the detection of peritoneal implants
CT is the imaging modality of choice for staging ovarian 
cancer. However, CT is limited in detecting small perito-
Figure 11. Bowel involvement in ovarian cancer. Contrast-enhanced com-
puted tomography image showing symmetrical nodular thickening (arrow-
heads) of the ileal loops in a case of ovarian cancer
A B
 Ovarian peritoneal carcinomatosis
e507© Pol J Radiol 2018; 83: e500-e509
Table 2. Differential diagnosis and computed tomography  mimics of peritoneal carcinomatosis
Carcinomatosis mimics Imaging features
Tuberculous peritonitis Three types – wet, fixed fibrotic, and dry plastic types. Young age, presence of free or loculated ascites, necrotic lymph 
nodes, matted bowel loops, and smooth peritoneal thickening confirms the diagnosis [24]
Peritoneal  
lymphomatosis
Associated findings of splenomegaly, aneurysmal dilatation of bowel loop segment, confluent homogeneously enhancing 
non-necrotic lymph nodes encasing the vessels producing a ‘sandwich sign’ [25] 
Primary peritoneal  
mesothelioma
Older age of presentation, strong association of asbestos exposure, two imaging patterns – nodular mass like large confluent 
masses and diffuse nodular thickening of peritoneum, no calcification, ascites (loculated or diffuse) with omental caking [26]
Pseudomyxoma peritonei Gelatinous ascites causing classical scalloping of the surface of abdominal organs [27]
Peritoneal sarcomatosis Associated with gastrointestinal stromal tumour, liposarcoma, and leiomyosarcoma. Distinguishing imaging features include 
heterogeneous bulky masses, hypervascularity with or without hemoperitoneum and variable presence of ascites [28]
Desmoplastic small  
round cell tumour
Rare aggressive malignancy that occurs in adolescents and young adults, mostly male, and carries a poor prognosis. 
Imaging features are characterised by single or multiple peritoneal masses in the omentum or paravesical region,  
which spread later to the entire abdominal cavity [29]
Splenosis Spontaneous auto-transplantation of splenic tissue after traumatic injury or splenectomy, 99mTcechnetium-labelled RBC 
scintigraphy with SPECT/CT imaging is the modality of choice for diagnosis [30]
Melanosis Unusual condition characterised by either focal or diffuse brown or black pigmentation of the peritoneum, usually 
surgico-pathological diagnosis; associated with various causes like metastatic melanoma, mature ovarian cystic teratoma, 
ovarian serous cystadenoma, enteric duplication cyst, peritoneal cyst [31]
Sclerosing peritonitis Chronic inflammatory condition of the peritoneum with an unknown aetiology, eventually progresses to sclerosis and 
membrane formation with subsequent cocoon formation. Imaging features are central accumulation of the small 
intestine encased by a dense membrane, intestinal obstruction, ascites, calcification bowel serous surface [32]
Omental infarct Fatty, large (> 5 cm) encapsulated mass, with soft-tissue stranding adjacent to the ascending colon [33]
Fat saponification Sequelae of pancreatitis resulting in mesenteric and retroperitoneal fat necrosis. Imaging shows scattered tiny soft tissue 
density nodules and fluid in vicinity of inflammation [33]
Figure 13. Lesser sac deposit in ovarian cancer. Contrast-enhanced comput-
ed tomography image showing metastatic deposits in between pancreas 
and stomach (arrowhead) and in gastrosplenic ligament (dashed arrow)
Figure 14. Perihepatic deposits in ovarian cancer. Axial contrast-enhanced 
computed tomography images showing: A) deposits in the falciform liga-
ment (arrowheads), periportal region; B) around gallbladder fossa (dashed 
arrow) with perihepatic and perisplenic enhancing deposits (arrows)
neal metastases. The sensitivity and specificity of CT in 
detecting tumour implants larger than 1 cm range from 
85-93% and 91-96%, respectively, but the sensitivity de-
creases to 25-50% in detecting implants that are 1 cm or 
smaller. MRI combining delayed gadolinium-enhanced 
imaging and diffusion-weighted MR imaging (DWM-
RI) is more accurate than CT for estimating peritoneal 
tumour burden [34]. Low et al. [35] have shown that MRI 
is superior to CT in estimating peritoneal cancer index, 
with sensitivity 95%, specificity 70%, and accuracy 88%, 
A
B
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Resectable disease that requires surgical  
subspecialty expertise
Subcapsular implants with hepatic parenchymal invasion
Limited hepatic parenchymal metastases
Bladder or ureteral invasion
Bowel serous deposits
Potentially nonresectable disease 
Extensive involvement of small bowel or mesenteric root





Metastatic implants near right hepatic vein
Implants > 2 cm in diameter in diaphragm, lesser sac, 
porta hepatis, gallbladder fossa, falciform ligament, 
gastrosplenic or gastrohepatic ligament
Figure 15. Diagram showing resectable and non-resectable parameters of ovarian cancer 
compared to CT, which had sensitivity 55%, specificity 
86%, and accuracy 63%. DWMRI with a high b-value 
(e.g. 800 s/mm2) increases the specificity in peritoneal 
carcinomatosis detection because of better suppression of 
the bowel contents, and the combination of DW-MRI and 
contrast-enhanced MRI further improve the detection ac-
curacy [36]. For treatment response evaluation, functional 
imaging with DWMRI or PET-CT is recommended. Post-
operative inflammation and oedema would result in high 
ADC, in contrast to tumours that have low ADC, allowing 
for differentiation of disease recurrence from postoper-
ative fibrosis and inflammation. DWMRI is superior to 
PET-CT in detecting perihepatic and serous deposits be-
cause of physiological uptake in the liver and bowel and 
respiratory motion interference [37]. PET-CT is a helpful 
imaging adjunct in the presence of rising tumour markers 
but equivocal CT or MRI, in detecting disease recurrence 
in ovarian cancer [38].
Conclusions
Accurate peritoneal anatomy and knowledge of imag-
ing features of peritoneal carcinomatosis is essential for 
appropriate management and care of patents with ovar-
ian cancer. It is important to be aware of the various re-
sectable and nonresectable parameters of ovarian cancer 
(Figure 15). CT is the most widely used imaging modality 
for assessment; however, MR with advanced functional 
tools can be helpful in assessing the tumour response to 
treatment.
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